Pathophysiology and clinical presentation
In the last years, there have been sustained efforts in the genetic field to elucidate the continuum between the genotype and phenotype of HCM as well as a treatment approach. To confirm a suspicion of HCM and a genotypic diagnosis, a genetic analysis is recommended (class of recommendation I, level of evidence B).\(^2\) In an overwhelming percentage of cases, the disease is caused by a single heterozygous mutation. In up to 75% of patients, the mutation appears in genes encoding myosin-binding protein C and β-myosin heavy chain.\(^3\) The molecular and cellular mechanisms are not completely understood,
but the disarray of the fibers, intercellular junction impairment, and replacement of cardiomyocytes with fibrotic tissue seem to be the main determinants of the pathogenesis. Thus, the clinical manifestation of HCM involves a wide spectrum of symptoms and severities, from asymptomatic or light effort dyspnea to syncope or sudden cardiac death, the latter being sometimes a single expression of the disease.

The new genetic data, suggesting such a great variation in disease expression, have provided a different perspective on the management of patients with HCM. The phenotypes of HCM (LV hypertrophy, LV outflow tract obstruction [LVOTO], fibrosis, myocardial ischemia, mitral regurgitation, and diastolic dysfunction) should be correlated with their clinical presentations heart failure, atrial fibrillation or stroke, angina, and sudden cardiac death.

In addition to the classic expression of HCM as LVOTO, a smaller proportion of patients will present atypical morphological patterns such as apical HCM, mid-cavity obstruction, or right ventricular hypertrophy. It is also clinically important to distinguish the minority of patients with significant LVOT obstruction but with a relatively mild septal hypertrophy (defined as a wall thickness exceeding 14 mm but lower than 18 mm). This phenotype is very difficult to treat by invasive methods, and in 2015, Ferrazzi et al. described a totally innovative approach to treatment.

Role of multimodality imaging in surgical decision making

Integrated multimodality imaging, including transthoracic echocardiography (TTE), 2- or 3-dimensional transesophageal echocardiography (TEE), stress echocardiography, and cardiac magnetic resonance (CMR), has helped identify multiple aspects of the various clinical presentations of HCM and has provided answers to management questions.

In 2015, the European Association of Cardiovascular Imaging expert consensus emphasized the important role of imaging in evaluating the risk of sudden cardiac death at 5 years, showing that half of the 8 criteria were based on a multi-imaging protocol. Integrated perioperative multimodality imaging techniques are crucial in surgical decision making. Comprehensive data such as the mechanism of LVOTO, the amount (extension, width, and depth) of the myocardium to be excised, and the anatomy and function of the mitral apparatus (and therefore the mechanism of mitral regurgitation) can all be assessed using standardized protocols for TTE, TEE, and CMR. In the recent years, preoperative CMR has played an increasing role in guiding the surgical planning.

Transthoracic echocardiography is recommended by consensus in all patients with HCM, and it should be done every 1 to 2 years in patients in stable condition. A TTE report in patients with HCM should contain standardized data about the LV diameter, thickness of the interventricular septum (IVS) and LV posterior wall in all segments, as well as the anterior-posterior diameter of the left atrium. Left ventricular volumes and ejection fraction should be calculated using the Simpson biplane method, and the LV mass, using the Devereux formula.

FIGURE 1 Results of transesophageal echocardiography: preoperative images showing left ventricular obstruction (A and D); postoperative images in patient 1 (B and C) and patient 2 (E and F) showing resolution of the obstruction as a result of myectomy and cutting of fibrotic secondary chordae.
Peak systolic and peak early diastolic mitral annular velocities should be assessed from septal and lateral sites in order to estimate the filling pressures. The systolic anterior motion of the mitral valve (MV) is a hallmark of LVOTO, and its severity should be recorded. The anterior or leaflet elongation and its mobility sometime determine mitral regurgitation, resulting in a posterior and lateral mitral regurgitation jet.

Color Doppler echocardiography is recommended for the semiquantitative evaluation of mitral regurgitation severity.\(^5,6\) If a central mitral regurgitation jet or multiple jets are observed, TEE should be performed to assess a particular mechanism of the mitral regurgitation. In HCM patients presenting with atrial fibrillation, the assessment of left atrial dysfunction (left atrial dimensions, volume, and remodeling) has shown to predict the clinical course of atrial fibrillation.\(^7\)

Obstruction is evaluated by measuring the LVOT gradient at rest or during stress conditions. Resting LVOT obstruction is defined as a peak gradient exceeding 30 mm Hg, and it is observed in up to one-third of patients with HCM. Another one-third of patients develop this gradient through Valsalva maneuvers or during stress. Stress echocardiography is used when a higher gradient is suspected, and it is assessed using an exercise protocol to decide on optimal management. Intraoperative TEE is performed to visualize the ventricular septum and MV apparatus. It is also used to accurately assess the maximal thickness septum for the myectomy, the apical extent of the septal excision, and MV abnormalities (such as annular calcifications, slack chordae, abnormal papillary muscle insertion, or fibrotic secondary chordae). Finally, it is the main modality used in the operating room to evaluate the early postprocedural outcome in order to confirm the absence of obstruction, normal MV function, and the absence of iatrogenic complications (mainly an IVS defect) (FIGURE 1A–1F).

Cardiac magnetic resonance emerges as a unique method of tomographic reconstruction of the LV septum, due to its excellent spatial resolution. It offers a reliable quantification of LV ejection fraction in HCM and may aid the assessment of LV function in cases when the quality of an echocardiographic image is suboptimal or in the presence of atypical patterns. Moreover, current CMR techniques provide detailed anatomical and functional data for determining LVOTO, such as IVS geometry, flow direction,\(^8\) and the elements of the MV apparatus that may contribute to obstruction. Therefore, owing to its higher spatial resolution, CMR may improve the diagnosis of HCM by providing additional information when echocardiography is suboptimal or nondiagnostic (FIGURE 2).

The late gadolinium enhancement (LGE) technique is based on the concept that tissue with an increased extracellular space will show a larger amount of a contrast agent, which is an extracellular substance. The current LGE algorithms provide such a high contrast-to-noise ratio that even small amounts of myocardial fibrosis can be visualized. Myocardial fibrosis is shown to be a strong independent predictor of cardiac outcome and evolution of the systolic function in patients with HCM. However, several studies have revealed that the adverse outcome is affected not by the pattern of distribution but rather by the total amount of LGE.\(^8,9\) (FIGURES 3 and 4).

T1 mapping is emerging as a promising method for the direct quantification of even very small or diffuse amounts of fibrosis, but research is ongoing on the use of T1 mapping in patients with HCM with no firm evidence yet.

Preoperative CMR has become increasingly used to guide surgical planning and to monitor invasive treatment procedures in HCM. It is
Therefore, to achieve successful outcomes with a low complication rate, the procedures must be performed by highly trained cardiac surgeons and cardiologists.

For a long time, alcohol septal ablation was the treatment of choice for HOCM. This technique uses transcoronary ethanol administration via a percutaneous approach to reduce the outflow tract gradient by causing a localized septal infarction with septal thinning. However, the procedure has some limitations, most importantly the fact that it cannot repair MV abnormalities that contribute to outflow obstruction. It is also associated with numerous potential complications, including an increased risk of ventricular tachyarrhythmia due to septal scarring or a reduction in the septal thickness that cannot be predicted beforehand. Therefore, this procedure is indicated only in carefully selected patients with severe LVOT obstruction and symptoms unresponsive to medical therapy.

Invasive treatment of the left ventricular gradient in hypertrophic obstructive cardiomyopathy There are 2 options for invasive therapy in patients with hypertrophic obstructive cardiomyopathy (HOCM): septal myectomy and catheter-based alcohol septal ablation. Both methods can be performed to relieve heart failure in patients with HCM with LV outflow obstruction and symptoms unresponsive to medical therapy. Both procedures require specific operator and institutional experience because HCM is seen relatively rarely in general cardiology practice. Therefore, to achieve successful outcomes with a low complication rate, the procedures must be performed by highly trained cardiac surgeons and cardiologists.

FIGURE 5 Preoperative cardiac magnetic resonance reconstruction of septal morphology, showing the measurements of the maximal septal thickness at different ventricular levels, using short-axis contiguous slices in a step-by-step process of reconstruction of thickness and length of the hypertrophied portion of the septum to be excised.
selected patients with HCM, mainly those who are inoperable.

In the last years, the guidelines of American College and American Heart Association as well as those of the European Society of Cardiology have indicated septal myectomy as the gold standard treatment (ie, class I recommendation) for relief of LVOTO and severe heart failure symptoms in patients with HCM with marked gradients (≥50 mm Hg) at rest or with provocation and significant symptoms unresponsive to medications. More importantly, myectomy remains the only option in patients with outflow obstruction and associated abnormalities of the MV apparatus that require surgical correction.

Due to the excellent results of the surgical treatment, Maron et al have recently suggested that despite the 2011 guidelines on HCM, myectomy should not be considered as the last therapeutic option for patients with severe symptoms, and, given the highly favorable benefit-to-risk ratio, providing a prolonged lifespan and a better quality of life, should be performed even in patients in the New York Heart Association functional class II.

Despite recommendations on surgical therapy, in Europe, the invasive treatment of LVOTO was mainly represented by alcohol septal ablation, including some countries, such as Germany and Switzerland, with previous important myectomy programs. During the last years, the surgical therapy of HCM in Europe has shown an increasing trend, mainly due to 2 reasons: the evidence of frequent failures of alcohol septal ablation as well as the abnormalities of the MV leaflets which contribute importantly to LVOTO in many (probably most) patients with HCM and can be resolved only by surgery.

The most experienced European surgical centers are in Monza (Italy) and in Rotterdam (the Netherlands). They have developed major myectomy programs with results that are similar, in terms of operative mortality (≤1%) and long-term clinical improvement and survival, to those of some of the most qualified centers in the United States, such as the Mayo Clinic and the Cleveland Clinic.

In Bucharest, Romania, we started a myectomy program in 2015, and we have operated 72 patients so far, with no mortality and resolution of the LV gradient in all cases.

**Evolution of surgical treatment: not only myectomy**

The first myectomy for obstructive HCM was performed in 1950 by Cleland et al. In the 1960s, Morrow et al proposed the transaortic resection of a small amount of muscle from the proximal ventricular septum, a technique generally described as classic myectomy.

For a short time, in the late 1970s, replacement of the MV with prosthesis was proposed as an alternative to septal myectomy. Nowadays, MV replacement is reserved for highly selected HCM patients with primary MV abnormalities not amenable to repair due to significant risks associated with prosthetic valves, such as limited durability, infection, thromboembolism, and anticoagulation.

Over the past 30 years, myectomy has evolved from the classic Morrow operation to a more extended septal myectomy guided by preoperative cardiovascular magnetic resonance and intraoperative TEE. Extending the myectomy beyond the point of mitral–septal contact is important to obtain relief of the outflow gradient because failure to achieve this surgical target is routinely associated with a persistent gradient. Therefore, the “classic” myectomy requires relevant operator and institutional experience. As mentioned above, there are only a few myectomy centers in the world, mainly in the United States. In Europe, experienced centers are located in Italy, Belgium, the Netherlands, England, and Israel. This is mainly because it is difficult to develop standard surgical approaches to the treatment of this disease, as it requires a deep septal myectomy and exposes patients to serious complications, such as postoperative ventricular septal defect or free wall rupture. Therefore, the current view is that myectomy should be discouraged in small community hospitals and should be performed only in “centers of excellence” for HCM treatment.

On the other hand, there are no data on the learning curve for the operator. In 2017, of the most experienced myectomy surgeons in the world published an expert opinion in which they stated that the number of septal myectomy surgeons is too low for the great number of patients who need this procedure.

In recent years, various surgical approaches have been developed to correct MV abnormalities, including transaortic extension or plication of the anterior mitral leaflet. This was due to a wide range of MV abnormalities present in patients with obstructive HCM, such as elongated or calcified MV leaflets and fibrotic and/or retracted secondary chordae. All these abnormalities were demonstrated to be involved in the pathophysiology of the systolic anterior motion of the MV and outflow obstruction.

In 2015, transaortic cutting of fibrotic secondary chordae, in combination with a shallow septal myectomy, was shown by Ferrazzi et al to move the MV apparatus to a more posterior position away from the septum, thereby augmenting the anterior MV surface, enlarging the outflow tract, preventing displacement of the MV into the LV outflow tract, and abolishing the outflow gradient. Such an approach was reported to improve outcomes in patients with obstructive HCM and severe heart failure. When we started a myectomy program in our center, we decided to use this technique in
all patients, regardless of the septal thickness. It allowed us to perform a relatively shallow myectomy in all patients. The exact dimension of the septal myectomy (Figures 6 and 7) was calculated using multimodal imaging and constituted one-third of the septal thickness, as proposed by the same team of Professor Ferrazzi. In our opinion, the surgical comfort of the operator is essential for an inexperienced myectomy surgeon. This is another reason why we started the myectomy program in Romania using the technique by Ferrazzi et al. In all 72 patients operated at our institution, we used a “one piece” myectomy tailored exactly one-third of the initial septal thickness, with particular attention to pass the equator of the LV whenever possible. The precise dimensions of the segment undergoing myectomy was selected based
on CMR, TEE, and TTE measurements. A careful mobilization of the papillary muscles and cutting of all fibrotic secondary chordae (FIGURE 8) allowed us to abolish the LV outflow gradient and preserve the MV in all patients, with no mortality and major complications.

Our experience and that of Dr. Ferrazzi with cutting secondary chordae in combination with a shallow septal myectomy show that this novel approach to surgical treatment of HOCM, which reduces the technical challenges of this procedure as well as the need for deep septal resection and/or MV replacement, could improve the access of patients with HOCM to sevial myectomy.

**Final remarks** This review is an update on the management of patients with HOCM, with particular focus on recent advances in surgical treatment. As we acknowledge the complexity of the disease variants even in the same family. The improvement in the understanding of its pathophysiology made it possible to correlate the phenotypes with their clinical presentations, which led to the development of standardized protocols including multimodality imaging techniques.

It is increasingly evident today that septal ablation is not able to address all the mechanisms of the LVOT gradient, especially MV involvement. Therefore, septal myectomy is the method of choice, with very good and reproducible results. As a result of recent advances in the complex surgical treatment of HOCM, addressing not only the septum but also the MV, the procedure of deep myectomy could be simplified and the mitral regurgitation properly corrected.

**REFERENCES**


